Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O6-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs

DNA Repair

Volumn 8, Issue 1, 2009, Pages 72-86

  Roos, Wynand P ^a   Nikolova, Teodora ^a   Quiros, Steve ^a   Naumann, Steffen C ^a   Kiedron, Olivia ^a   Zdzienicka, Małgorzata Z ^b   Kaina, Bernd ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Aberrations; Apoptosis; Brca2; DNA double strand breaks; Homologous recombination; MGMT; NHEJ; SCEs; Temozolomide; XRCC2

Indexed keywords

6 O METHYLGUANINE; BRCA2 PROTEIN; DNA METHYLTRANSFERASE; HISTONE H2AX; METHYLNITRONITROSOGUANIDINE; PROTEIN XRCC2; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; DNA STRAND BREAKAGE; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENETIC TRANSFECTION; HOMOLOGOUS RECOMBINATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SISTER CHROMATID EXCHANGE;

ANIMALS; APOPTOSIS; BRCA2 PROTEIN; CELL DEATH; CHO CELLS; CHROMOSOME ABERRATIONS; CRICETINAE; CRICETULUS; DACARBAZINE; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-BINDING PROTEINS; DOWN-REGULATION; FLUORESCENT ANTIBODY TECHNIQUE; GUANINE; MICE; MUTATION; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RECOMBINATION, GENETIC; SISTER CHROMATID EXCHANGE; TRANSFECTION;

EID: 56549122306     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2008.09.003     Document Type: Article

References (62)

1. Fiddler W. The occurrence and determination of N-nitroso compounds. Toxicol. Appl. Pharmacol. 31 (1975) 352-360
2. Tew K.D., Colvin M., and Chabner B.A. Alkylating agents. In: Chabner B.A., and Longo D. (Eds). Cancer Chemotherapy: Principles and Practice. 2nd ed. (1996), J.B. Lippincott Co., Philadelphia 297-332
3. Beranek D.T. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat. Res. 231 (1990) 11-30
4. 6-methylguanine. Mutagenesis 17 (2002) 483-487
5. Kaina B., Christmann M., Naumann S., and Roos W.P. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst.) 6 (2007) 1079-1099
6. Gerson S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 4 (2004) 296-307
7. 6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 12 (1991) 1857-1867
8. Pegg A.E. Repair of O(6)-alkylguanine by alkyltransferases. Mutat. Res. 462 (2000) 83-100
9. 6-alkylguanine-DNA alkyltransferase. Carcinogenesis 24 (2003) 625-635
10. Day III R.S., Ziolkowski C.H., Scudiero D.A., Meyer S.A., Lubiniecki A.S., Girardi A.J., Galloway S.M., and Bynum G.D. Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains. Nature 288 (1980) 724-727
11. Brozmanova J., Kleibl K., Vlckova V., Skorvaga M., Cernakova L., and Margison G.P. Expression of the E. coli ada gene in yeast protects against the toxic and mutagenic effects of N-methyl-N′-nitro-N-nitrosoguanidine. Nucleic Acids Res. 18 (1990) 331-335
12. 6-alkylguanine and N-alkylpurines to the formation of sister chromatid exchanges, chromosomal aberrations, and gene mutations: new insights gained from studies of genetically engineered mammalian cell lines. Environ. Mol. Mutagen. 22 (1993) 283-292
13. 6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models. Mutat. Res. 381 (1997) 227-241
14. Tominaga Y., Tsuzuki T., Shiraishi A., Kawate H., and Sekiguchi M. Alkylation-induced apoptosis of embryonic stem cells in which the gene for DNA-repair, methyltransferase, had been disrupted by gene targeting. Carcinogenesis 18 (1997) 889-896
15. 6-alkylguanine DNA lesions trigger apoptosis. Carcinogenesis 19 (1998) 369-372
16. 6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res. 60 (2000) 5815-5824
17. 6-methylguanine residues in genomic DNA and production of sister-chromatid exchanges, mutations and lethal events in a Mer-human tumor cell line. Mutat. Res. 314 (1994) 99-113
18. Kaina B. Mechanisms and consequences of methylating agent-induced SCEs and chromosomal aberrations: a long road traveled and still a far way to go. Cytogenet. Genome Res. 104 (2004) 77-86
19. 6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene 23 (2004) 359-367
20. Branch P., Aquilina G., Bignami M., and Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362 (1993) 652-654
21. de Wind N., Dekker M., Berns A., Radman M., and te Riele H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 82 (1995) 321-330
22. Fishel R., Lescoe M.K., Rao M.R., Copeland N.G., Jenkins N.A., Garber J., Kane M., and Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75 (1993) 1027-1038
23. Hickman M.J., and Samson L.D. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 10764-10769
24. Karran P., and Bignami M. DNA damage tolerance, mismatch repair and genome instability. Bioessays 16 (1994) 833-839
25. 4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 6443-6447
26. Mojas N., Lopes M., and Jiricny J. Mismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA. Genes Dev. 21 (2007) 3342-3355
27. 6-methylguanine adducts. Mol. Cell. 22 (2006) 501-510
28. 6-methylguanine triggered apoptosis, SCEs and chromosomal aberrations. DNA Repair (Amst.) 3 (2004) 359-368
29. Golding S.E., Rosenberg E., Khalil A., McEwen A., Holmes M., Neill S., Povirk L.F., and Valerie K. Double strand break repair by homologous recombination is regulated by cell cycle-independent signaling via ATM in human glioma cells. J. Biol. Chem. 279 (2004) 15402-15410
30. D'Atri S., Tentori L., Lacal P.M., Graziani G., Pagani E., Benincasa E., Zambruno G., Bonmassar E., and Jiricny J. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol. Pharmacol. 54 (1998) 334-341
31. Caporali S., Falcinelli S., Starace G., Russo M.T., Bonmassar E., Jiricny J., and D'Atri S. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol. Pharmacol. 66 (2004) 478-491
32. Stojic L., Mojas N., Cejka P., Di Pietro M., Ferrari S., Marra G., and Jiricny J. Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev. 18 (2004) 1331-1344
33. Roos W.P., Batista L.F., Naumann S.C., Wick W., Weller M., Menck C.F., and Kaina B. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O(6)-methylguanine. Oncogene 26 (2007) 186-197
34. Helleday T., Lo J., van Gent D.C., and Engelward B.P. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst.) 6 (2007) 923-935
35. van Gent D.C., and van der Burg. M. Non-homologous end-joining, a sticky affair. Oncogene 26 (2007) 7731-7740
36. Wyman C., Ristic D., and Kanaar R. Homologous recombination-mediated double-strand break repair. DNA Repair (Amst.) 3 (2004) 827-833
37. Osman F., and Whitby M.C. Exploring the roles of Mus81-Eme1/Mms4 at perturbed replication forks. DNA Repair (Amst.) 6 (2007) 1004-1017
38. Errami A., Smider V., Rathmell W.K., He D.M., Hendrickson E.A., Zdzienicka M.Z., and Chu G. Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants. Mol. Cell Biol. 16 (1996) 1519-1526
39. van Putten J.W.G., Groen H.J.M., Smid K., Peters G.J., and Kampinga H.H. End-joining deficiency and radiosensitization induced by gemcitabine. Cancer Res. 61 (2001) 1585-1591
40. Errami A., He D.M., Friedl A.A., Overkamp W.J., Morolli B., Hendrickson E.A., Eckardt-Schupp F., Oshimura M., Lohman P.H., Jackson S.P., and Zdzienicka M.Z. XR-C1, a new CHO cell mutant which is defective in DNA-PKcs, is impaired in both V(D)J coding and signal joint formation. Nucleic Acids Res. 26 (1998) 3146-3153
41. Thacker J., Tambini C.E., Simpson P.J., Tsui L.C., and Scherer S.W. Localization to chromosome 7q36.1 of the human XRCC2 gene, determining sensitivity to DNA-damaging agents. Hum. Mol. Genet. 4 (1995) 113-120
42. Kraakman-van der Zwet M., Overkamp W.J., van Lange R.E., Essers J., van Duijn-Goedhart A., Wiggers I., Swaminathan S., van Buul P.P., Errami A., Tan R.T., Jaspers N.G., Sharan S.K., Kanaar R., and Zdzienicka M.Z. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol. Cell Biol. 22 (2002) 669-679
43. Newlands E.S., Blackledge G.R., Slack J.A., Rustin G.J., Smith D.B., Stuart N.S., Quarterman C.P., Hoffman R., Stevens M.F., Brampton M.H., et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer 65 (1992) 287-291
44. Denny B.J., Wheelhouse R.T., Stevens M.F., Tsang L.L., and Slack J.A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33 (1994) 9045-9051
45. Roos W.P., Binder A., and Bohm L. Determination of the initial DNA damage and residual DNA damage remaining after 12 h of repair in eleven cell lines at low doses of irradiation. Int. J. Radiat. Biol. 76 (2000) 1493-1500
46. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
47. Renart J., Reiser J., and Stark G.R. Transfer of proteins from gels to diazobenzyloxymethyl-paper and detection with antisera: a method for studying antibody specificity and antigen structure. Proc. Natl. Acad. Sci. U.S.A. 76 (1979) 3116-3120
48. 6-methylguanine-DNA methyltransferase activity in breast and brain tumors. Int. J. Cancer 61 (1995) 321-326
49. Perry P., and Wolff S. New Giemsa method for the differential staining of sister chromatids. Nature 251 (1974) 156-158
50. Foray N., Randrianarison V., Marot D., Perricaudet M., Lenoir G., and Feunteun J. Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2. Oncogene 18 (1999) 7334-7342
51. Johnson R.D., Liu N., and Jasin M. Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination. Nature 401 (1999) 397-399
52. Xia F., Taghian D.G., DeFrank J.S., Zeng Z.C., Willers H., Iliakis G., and Powell S.N. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 8644-8649
53. Feldmann E., Schmiemann V., Goedecke W., Reichenberger S., and Pfeiffer P. DNA double-strand break repair in cell-free extracts from Ku80-deficient cells: implications for Ku serving as an alignment factor in non-homologous DNA end joining. Nucleic Acids Res. 28 (2000) 2585-2596
54. Chu G. Double strand break repair. J. Biol. Chem. 272 (1997) 24097-24100
55. Zhang H., Marra G., Jiricny J., Maher V.M., and McCormick J.J. Mismatch repair is required for O(6)-methylguanine-induced homologous recombination in human fibroblasts. Carcinogenesis 21 (2000) 1639-1646
56. Nowosielska A., Smith S.A., Engelward B.P., and Marinus M.G. Homologous recombination prevents methylation-induced toxicity in Escherichia coli. Nucleic Acids Res. 34 (2006) 2258-2268
57. Cejka P., Mojas N., Gillet L., Schar P., and Jiricny J. Homologous recombination rescues mismatch-repair-dependent cytotoxicity of S(N)1-type methylating agents in S. cerevisiae. Curr. Biol. 15 (2005) 1395-1400
58. Tsaryk R., Fabian K., Thacker J., and Kaina B. Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide. Cancer Lett. 239 (2006) 305-313
59. Darroudi F., and Natarajan A.T. Cytological characterization of Chinese hamster ovary X-ray-sensitive mutant cells xrs 5 and xrs 6. I. Induction of chromosomal aberrations by X-irradiation and its modulation with 3-aminobenzamide and caffeine. Mutat. Res. 177 (1987) 133-148
60. Kaina B., and Aurich O. Dependency of the yield of sister-chromatid exchanges induced by alkylating agents on fixation time. Possible involvement of secondary lesions in sister-chromatid exchange induction. Mutat. Res. 149 (1985) 451-461
61. Esashi F., Galkin V.E., Yu X., Egelman E.H., and West S.C. Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2. Nat. Struct. Mol. Biol. 14 (2007) 468-474
62. Shim K.S., Schmutte C., Tombline G., Heinen C.D., and Fishel R. hXRCC2 enhances ADP/ATP processing and strand exchange by hRAD51. J. Biol. Chem. 279 (2004) 30385-30394